A retrospective study from our institution in patients with HER2+ breast cancer BrM found that receipt of multiple HER2-directed ST agents within a 1mo window of SRS may increase the risk of developing radiation necrosis in these patients.19 The gene discussed is ERBB2; the disease is breast carcinoma.